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Locally advanced pancreatic cancer — new therapeutic challenges 
Michał Piątek1, Sergiusz Nawrocki2, 3
The overall survival rate of patients with pancreatic ductal adenocarcinoma remains extremely poor, and the only 
potentially curative treatment is radical surgery. There are three subgroups among the patients: primary resectable, 
metastatic and locally advanced pancreatic cancer. The term of locally ad advanced pancreatic cancer includes bor-
derline resectable pancreatic cancer (BRPC) and unresectable pancreatic cancer (URPC). As in the case of BRPC, the 
strategy of induction treatment may convert the inoperable tumour into a resectable one. As in the case of URPC, 
the optimal standard of treatment is unknown. Recent advances in systemic treatment such as FOLFIRINOX (5-fluo-
rouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel as well as the optimisation of local 
treatment  such as stereotactic radiotherapy (SBRT — stereotactic body radiation therapy) should be incorporated 
into future trials dedicated for BRPC and URPC. 
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Introduction 
Pancreatic cancer is a disease with an extremely high 
mortality rate — it ranks fifth among the causes of death 
for malignant cancers in developed countries. It is one of 
the few cancers in which there has been no significant pro-
gress in treatment results for the last few decades. Within 
the last 30 years, the chances of 5-year survival has grown 
from about 2% to 5% [1]. At the time of diagnosis, only 
10% of patients have a resectable tumour and 60% have 
distant metastases while in 30% of cases the tumour is lo-
cally advanced [2].
Practical clinical division into sub-groups
Primarily the resectable group of patients is character-
ised by the lack of distant metastases, the lack of infiltration 
of the vascular structures within the celiac axis (CA), the su-
perior mesenteric artery (SMA), the common hepatic artery 
(CHA), the superior mesenteric vein (SMV), the portal vein 
(PV) with the admissible vein infiltration being < 180º of 
the vessel perimeter with the possibility of reconstruction 
[3, 4]. Even in the case of R0 resection, the 5-year survival 
rate in this group is as low as 15–20%, with median survival 
being about 20–24 months [5].  In the case of the R1 or R2 
resection, survival is usually less than 12 months, being on 
a comparable level as that of the locally advanced group 
[6, 7]. The rate of R1 resection reported in publications var-
ied between 20% and 75% [8, 9]. A standard treatment 
after the radical resection of patients is 6-month adjuvant 
chemotherapy [10].
Patients with systemic involvement have the worst prog-
noses. The main treatment method in this group is systemic 
treatment, mostly with chemotherapy. The clinical benefit 
over treatment with  5-fluorouracil administered in the form 
of weekly bolus doses and the slight improvement in overall 
survival made gemcitabine a standard method of palliative 
treatment in 1997 [11]. Recent developments in the treat-
ment of metastatic pancreatic cancer with new chemothera-
peutic regimens such as gemcitabine plus nab-paclitaxel or 
FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxalipla-
tin) led to a significant improvement in treatment results 
in comparison with gemcitabine in monotherapy [12, 13]. 
The comparison of FOLFIRINOX (FFX) with gemcitabine 
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showed a sinificant increase in the objective response rate 
(31.6% vs 9.4%), a significant prolongation of the survival 
period (11.1 vs 6.7 months) and a significant prolongation of 
progression-free survival (6.4 vs 3.3 months). In spite of such 
intensity of treatment and much larger toxicity in grade 3 
and 4, no deterioration of quality of life was observed among 
the patients treated with FFX [13]. Irrespective of the  initial 
doubts related to the large toxicity of FFX, this regimen was 
quickly introduced into clinical practice and until today it 
has been undergoing numerous modifications — these are 
mFOLFIRINOX (mFFX) which reflect the attempts to reduce 
toxicity accompanied with the preservation of the treatment 
efficacy [14–19].
The medium group of patients with a diagnosis of lo-
cally advanced neoplastic progress is characterised by the 
absence of distant metastases. However, some traces of 
the infiltration of adipose tissue around the arteries (SMA, 
CHA, CA) and/or the infiltration of veins (SMV, PV) with the 
involvement of > 180° of the vessel perimeter and the im-
possibility of its reconstruction is observed [3, 4]. This is the 
most heterogeneous group of patients among whom there 
are at the same time possibilities of radical surgery as well 
as palliative treatment only, and thus there are no definite 
standards of treatment. Given the above, it was necessary 
to distinguish a group of patients where the radical treat-
ment could be possible at any stage of the therapeutic 
process. Eventually the locally advanced pancreatic cancer 
patients were divided into a group with borderline resect-
able pancreatic cancer (BRPC) and a group with unresectable 
pancreatic cancer (URPC).
Borderline resectable pancreatic cancer
The term borderline resectable pancreatic cancer has a 
relatively short history and it was coined because it became 
clear that long term survival in pancreatic cancer was only 
possible in the case of R0 resection. Other developments 
in this matter were defining venous resections in pancrea-
toduodenectomy as feasible and safe procedures, accompa-
nied with the first reports of the possibilities of neoadjuvant 
treatment increasing the rate of R0 resections [20, 21].  
The radiological criteria which allow one to distinguish 
between resectable and non-resectable cancers were de-
scribed for the first time in 2001 [22]. In 2006, the National 
Comprehensive Cancer Network (NCCN) introduced the 
term “borderline resectability” to describe, in the most ac-
curate manner, the tumours which in a limited way involve 
the vascular system and whose primary resection, if possible, 
would leave the positive surgical margins and would require 
the application of neoadjuvant treatment. Until today no 
universal definition of BRPC has been coined, which has an 
adverse effect on the possibilities of comparing the results 
of the treatment, and, as a result of which no standards in 
treatment have been created. The most frequently quot-
ed definitions of BRPC were proposed by MD Anderson, 
America’s Hepatopancreatobiliary Association (AHBPA), the 
Society for Surgery of the Alimentary (SSO), NCCN and by the 
Intergroup trial, with the latter deserving special attention, 
as it does not use any subjective terminology and is easy to 
apply to the MRI protocols (Tab. I) [4, 23–25].
A great majority of clinical studies carried out so far deal-
ing with BRPC are retrospective, single centred and concern 
a small group of patients The value of these reports is lim-
ited by a diversity of the definitions of resectability and the 
multitude of possibilities of neoadjuvant treatment. In one 
such study, carried out in the MD Anderson Cancer Center, 
160 (7%) out of 2454 patients with a diagnosed pancreatic 
cancer were regarded as BRPC and treated with neoadjuvant 
therapy. The treatment was completed in 125 patients with 
66 undergoing radical resection and 62 of them R0 resec-
tion (94%). The median of overall survival in the group of 
66 who completed the treatment was 40 months, whilst 
in the remaining 94 patients who did not go through pan-
creatoduodenectomy, it was 13 months (p < 0.001) [26]. 
Given the limitations connected with the methodology of 
studies concerning BRPC, the meta-analyses suggest that 
neoadjuvant treatment with chemotherapy or chemora-
diation, based mostly on gemcitabine or 5-FU, allows for a 
radical surgery in 1/3 of patients and the prognoses in the 
group of patients does not differ much from the prognoses 
among the primarily resectable patients [27, 28]. In light 
of the new developments in the treatment of metastatic 
pancreatic cancer, in particular the FFX regimen, some at-
tempts have been made to introduce it to the treatment 
of locally advanced pancreatic cancer, including BRPC. In 
2014, the first published results on this issue concerned a 
prospective clinical trial with 18 patients with a diagnosis 
of BRPC, who first underwent neoadjuvant chemotherapy 
with FFX followed by a consecutive chemoradiation (50.4 
Gy + gemcitabine or capecitabine).  In the consecutive 
stage, 12 patients (66%) underwent radical surgery and in 
all of the cases the R0 was obtained (100%). With regards to 
the too short follow-up period, the final treatment results 
Table I. The definition of borderline resectable pancreatic cancer according to the Intergroup trial
SMV-PV SMA CHA CA
Tumour — vessel interface  > 180° 
of the vessel perimeter and/or 
the obliteration of the vessel with 
the possibility of performing safe 
resection and  reconstruction
Tumour — vessel interface  < 180° 
of the vessel perimeter
Tumour — vessel interface  
concerning a small segment with 
the possibility of performing safe 
resection and  reconstruction 
Tumour — vessel interface  < 180° 
of the vessel perimeter
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are missing; nevertheless 7 patients (58.3%) out of the 12 
who completed the treatment are still alive and 5 of them 
(41.7%) are free from progression (18–35 months from di-
agnosis), whereas 6 patients who did not complete the 
treatment, died (6.9–17.5 months from diagnosis). It must 
also be stressed that the adverse event rate in the 3rd and 4th 
grade was relatively low. The most frequent complications 
comprised nausea/vomiting (35.7%), neutropenia (14.3%) 
and diarrhoea (14.3%), and a large emphasis was laid on 
supportive care, such as, among others, the prophylactic 
application of granulocyte growth factor and antiemetic 
therapy with aprepitant — yet the toxicity of FFX did not 
have any negative influence on the completion of chemo-
radiation or mortality or peri-operative complications [29]. 
The largest undertaking devoted to BRPC is a multicentre 
pilot study, Alliance A021101, initiated by the Intergroup 
trial in 2013, in which the neoadjuvant treatment was based 
on 4 mFFX cycles followed by a consecutive chemoradiation 
with capecitabine. The results of this study are hoped to be 
a reference point for future BRPC studies [25].
Definitely non-resectable pancreatic cancer 
The distinction of BRPC from patients with a locally 
advanced pancreatic cancer resulted in the appearance of 
a group of patients with cancers with URPC — unresect-
able pancreatic cancer. The reports of the two carefully 
performed studies in this subject showed that in such cases, 
as opposed to BRPC, the possibility of obtaining resectability 
is extremely rare  (1/87 and 6/114 patients respectively), 
which, in consequence, means that long-term survival in 
this group is exceptionally rare [30, 31]. Given the above, 
the main objectives of treatment in patients with URPC is 
improvement of quality of life and the improvement of the 
survival period, as the course of the disease in this group 
of patients differs significantly from metastatic pancreatic 
cancer and requires analysis in separate protocols of clinical 
studies [32].
The optimal therapeutic standard in URPC is highly con-
troversial with many questions still remaining unanswered. 
The role of radiotherapy or chemotherapy in the treatment 
of URPC, now increasingly in use, as well as the effect of such 
treatment on overall survival is undoubtedly one of these 
questions. The data from the two largest trials carried out 
so far are contradictory. The first of them (FFCD/SFRO) com-
pared chemoradiation (60 Gy + cisplatin and 5-fluorouracil) 
with gemcitabine in monotherapy. In the group of patients 
treated with chemoradiation, the average overall survival 
time was only 8.6 months, whilst in the group treated with 
chemotherapy alone, it was 13 months (p < 0.03). It must be 
stressed that the treatment with radiotherapy was burdened 
with significant toxicity, which was caused by an extensive 
irradiation area and a large radiation dose — and finally 
this was the main cause of the deterioration of treatment 
outcomes in this group [33]. In the second trial (ECOG 4201) 
chemoradiation (50.4 Gy + gemcitabine) was compared with 
gemcitabine in monotherapy. The average overall survival 
in the group of patients treated with chemoradiation was 
11 months, whilst in the group treated with chemotherapy 
alone it was 9.2 months (p = 0.017). Significantly greater 
toxicity of treatment was observed in the chemoradiation 
arm:  as GI tract complications G3/4 (38 vs 14%, p = 0.03) and 
fatigue G3/4 (32 vs 6%, p = 0.006) [34]. Summarising the two 
above trials, it seems that adding radiotherapy to chemo-
therapy has some insignificant effects on the improvement 
of overall survival, yet it is burdened with large toxicity. 
The final attempt to establish the role of radiotherapy in 
the treatment of URPC was made in the RTOG 1201 trial, 
currently in progress, where after an initial 3-month chemo-
therapy: gemcitabine + nab-paclitaxel and the exclusion of 
the group with the disease progression, the patients were 
randomly assigned to consecutive chemoradiation (50.4 Gy 
+ capecitabine) or chemoradiation (63 Gy + capecitabine) 
or the continuation of chemotherapy [35]. 
Another issue related to the problems in the treatment 
of URPC is the optimal sequence of chemotherapy and 
chemoradiation. The recent analyses concerning the treat-
ment with primary chemotherapy followed by consecutive 
chemoradiation in comparison with primary chemoradia-
tion followed by consecutive chemotherapy point to the 
advantage of the first method of treatment over the latter. 
Primary chemotherapy carried for 2–3 months allows for 
the correct selection of the patients who could benefit 
from consecutive chemoradiation — the progression is 
observed in about 30% of patients after primary chemo-
therapy [36, 37]
The selection of an adequate cytostatic agent for treat-
ment with radiation, as the radio-sensitiser, is also contro-
versial among investigators. The largest meta-analysis so 
far, containing 229 patients and comparing gemcitabine 
with 5-fluorouracil associated with radiation, has proven 
the advantage of gemcitabine over 5-fluorouracil with re-
gards to 1-year survival (27.9–56.2% vs 18.3–31.6%, p = 
0.03), however, with regards to 6-month and 2-year sur-
vival, no differences were found between the groups [38]. 
A recent prospective clinical study, (SCALOP trial) compar-
ing chemoradiation based on capecitabine (2x 830 mg/m2 
on irradiation days) as opposed to gemcitabine (300 mg/
m2 every 7 days, 6 doses in total) preceded by a primary 
3-month chemotherapy, showed a significant prolonga-
tion of the survival period in the group with capecitabine 
(15.2 vs 13.4 months, p = 0.01); moreover, the treatment 
with capecitabine was characterised with a more favour-
able toxicity profile, both haematological (0 vs 18%), and 
non-haematological one (12 vs 26%). Contrary to gemcit-
abine, the administration of capecitabine during radiation 
could also affect the control of the disease from a systemic 
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point of view, which finally could translate into the improve-
ment of overall survival. Irrespective of the initially small 
number of patients participating in the above study (74 
subjects), capecitabine is now the most frequently associ-
ated with radiation in new protocols of pancreatic cancer 
chemotherapy [39]. The discussion of URPC treatment must 
point to the attempts of SBRT — stereotactic body radiation 
therapy alone or in combination with chemotherapy (Table 
II) [40–45]. The trials which have been carried out point to 
an effective local disease control in this method. The data 
concerning the safety of SBRT show very high late toxicity 
(ulceration, bleeding, perforation, mainly in the duodenal 
area), in the case of a single dose of SBRT. In the case of 
fractionation SBRT, the efficacy of treatment is comparable 
to conventional radiation with the safety of treatment kept 
at an acceptable level [40–48].
Conclusions and future directions for 
development 
Resection, carried out with healthy margins, still remains 
the only chance for curing pancreatic adenocarcinoma. 
In the group of patients with locally advanced tumours, 
there is a distinction between the radical treatment (BRPC) 
and palliative approach (URPC). Preoperative treatment 
is not a standard approach in the treatment of pancreatic 
cancer, nevertheless in the case of BRPC, the application of 
preoperative therapy naturally seems to be the only pos-
sibility of obtaining R0 resection. Given the above, a careful 
qualification of the patients into specific groups is critical 
for the selection of the therapeutic strategy. 
Distant metastases remain the main cause of the treat-
ment failure in pancreatic cancer. The improvement of the 
treatment results must be found first of all in better sys-
temic treatment. The progress in treatment obtained in 
metastatic pancreatic cancer, gained in such methods as 
FFX/mFFX or gemcitabine + nab-paclitaxel should be used 
for the treatment protocols of clinical studies in both BRPC 
and URPC [12, 13]. Given the autopsy results pointing to 
the 30% rate of deaths resulting from local progression, 
one must not forget about the necessity of local control 
improvement. In spite of many controversies concerning 
the adequacy of irradiation in locally advanced pancreatic 
cancer, both conventionally fractionated chemoradiation 
and SBRT are frequent constituents of treatment in the 
protocols of clinical studies. Although there have not been 
any studies comparing the two methods of irradiation, SBRT 
is growing in frequency. This reflects the improvement of 
the quality of life resulting from very effective and fast pain 
control (less use of analgesic agents) in SBRT and a shorter 
treatment period than in conventional chemoradiation (1–5 
days vs 5–6 weeks) [50]. There are reports which are based 
on molecular profiling, that point to the most probable 
method of disease progression. In one of the studies, it was 
shown that the loss of the DPC4 tumour suppressor gene 
was connected with an increased risk of metastatic disease, 
whilst its presence in the tumour tissues resulted in a more 
frequent local progression (p = 0.007) [49]. The possibility 
of predicting the method of disease progression (local vs 
distant) may in future be a justification for the use of local 
and/or systemic methods of treatment. Currently, the treat-
ment strategy both in BRPC and URPC, apart from surgical 
intervention (if it is possible), comprises the combination 
of systemic treatment and irradiation. So far the combina-
tion of FFX or mFFX with SBRT has not been studied. Such 
a combination may prove to be very effective in the treat-
ment of locally advanced pancreatic adenocarcinoma and 
definitely requires some further clinical research.
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Table II.  Selected clinical studies with SBRT in combination with chemotherapy (GEM, gemcitabine; 5-FU, 5-fluorouracil; GTX, gemcitabine, docetaxel, 
capecitabine) in locally advanced pancreatic cancer
Study Number  
of subjects 
 Treatment regimen Months 1-year local 
control  
Early toxicity 
G3/4
Late toxicity  
G3/4
Mahadevan (2010) 36 8–12 Gy x 3 + GEM 14.3 78% 8% G3 6% G3
Lominska (2011) 28 4–8 Gy x 3–5 + 5-Fu/GEM 5.9 86% 0 7.1% G3
Chuong (2012) 16 5–10 Gy x 5 + GTX 15.0 81% 0 5.3% G3
Tozzi (2013) 30 8 Gy x 5 11.0 86% 0 0
Gurka (2014)  10 5 Gy x 5
+ GEM 12.2 40% 0 0
Herman (multi- center, 2015) 49 6.6 Gy x 5
+ GEM 13.9 78% 12.2% 10.6%
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